Literature DB >> 22858277

Should patients 60 years and older undergo bridge to transplantation with continuous-flow left ventricular assist devices?

Jeremiah G Allen1, Arman Kilic, Eric S Weiss, George J Arnaoutakis, Timothy J George, Ashish S Shah, John V Conte.   

Abstract

BACKGROUND: Although left ventricular assist devices (LVADs) are now commonly used as a bridge to orthotopic heart transplantation (OHT), the upper patient age limit for this therapy has not been defined. Smaller studies have suggested that advanced age should not be a contraindication to bridge to transplantation (BTT) LVAD placement. The purpose of this study was to examine outcomes in patients 60 years and older undergoing BTT with continuous-flow LVADs.
METHODS: The United Network for Organ Sharing (UNOS) database was reviewed to identify first-time OHT recipients 60 years of age and older (2005-2010). Patients were stratified by preoperative support: continuous-flow LVAD, intravenous inotropic agents, and direct transplantation. Survival after OHT was modeled using the Kaplan-Meier method. All-cause mortality was examined using multivariable Cox proportional hazard regression.
RESULTS: Of 2,554 patients, 1,142 (44.7%) underwent direct transplantation, 264 (10.3%) had LVAD BTT, and 1,148 (45.0%) had BTT with inotropic agents. The mean age was 64±3 years, and 460 (18.0%) patients were women. Mean follow-up was 29±19 months. Survival differed significantly among the 3 groups. Patients with LVAD BTT had significantly lower survival after OHT compared with the other groups at 30 days and 1 year. This survival difference was no longer significant at 2 years after OHT or when deaths in the first 30 days were censored. LVAD BTT increased the hazard of death at 1 year by 50% (hazard ratio [HR], 1.50; 95% confidence interval [CI], 1.05-2.15; p=0.03), compared with patients who underwent direct transplantation.
CONCLUSIONS: This study represents the largest modern cohort in which survival after OHT has been evaluated in patients 60 years or older who received BTT. Older patients have lower short-term survival after OHT when BTT is carried out with a continuous-flow LVAD compared with inotropic agents or direct transplantation.
Copyright © 2012 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22858277     DOI: 10.1016/j.athoracsur.2012.06.009

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  4 in total

1.  Short and long term outcomes of 200 patients supported by continuous-flow left ventricular assist devices.

Authors:  Athanasios Tsiouris; Gaetano Paone; Hassan W Nemeh; Jamil Borgi; Celeste T Williams; David E Lanfear; Jeffrey A Morgan
Journal:  World J Cardiol       Date:  2015-11-26

2.  A mortality risk score for heart transplants after contemporary ventricular assist device bridging.

Authors:  Lauren V Huckaby; Laura M Seese; Gavin Hickey; Ibrahim Sultan; Arman Kilic
Journal:  J Card Surg       Date:  2020-12-07       Impact factor: 1.778

3.  Outcomes and predictors of early mortality after continuous-flow left ventricular assist device implantation as a bridge to transplantation.

Authors:  Anton Sabashnikov; Prashant N Mohite; Bartlomiej Zych; Diana García; Aron-Frederik Popov; Alexander Weymann; Nikhil P Patil; Rachel Hards; Massimo Capoccia; Thorsten Wahlers; Fabio De Robertis; Toufan Bahrami; Mohamed Amrani; Nicholas R Banner; André R Simon
Journal:  ASAIO J       Date:  2014 Mar-Apr       Impact factor: 2.872

Review 4.  Bio-artificial heart as ultimate treatment of end-stage heart failure.

Authors:  Francis E Smit; Pascal M Dohmen
Journal:  Med Sci Monit Basic Res       Date:  2014-10-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.